BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 27134145)

  • 1. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzales B; Zampeli E; Grivas E; Spiliadi C; Sotiropoulou M; Petraki K; Zografos K; Laoudi F; Sgouras D; Mentis A; Kasapidis P; Michopoulos S
    Eur J Intern Med; 2016 Jul; 32():84-90. PubMed ID: 27134145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication.
    Tepeš B; Vujasinović M; Šeruga M; Stefanovič M; Forte A; Jeverica S
    Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):676-83. PubMed ID: 26862930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
    Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori.
    Bardhan KD; Morton D; Perry MJ; Sanders DS; Morris P; Rowland A; Thompson M; Mitchell TR; Roberts PM
    Aliment Pharmacol Ther; 2001 Aug; 15(8):1199-204. PubMed ID: 11472323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
    Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice.
    McNicholl AG; Marin AC; Molina-Infante J; Castro M; Barrio J; Ducons J; Calvet X; de la Coba C; Montoro M; Bory F; Perez-Aisa A; Forné M; Gisbert JP;
    Gut; 2014 Feb; 63(2):244-9. PubMed ID: 23665990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial.
    Heo J; Jeon SW; Jung JT; Kwon JG; Lee DW; Kim HS; Yang CH; Park JB; Park KS; Cho KB; Lee SH; Jang BI;
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1361-6. PubMed ID: 25867608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial.
    Chung JW; Jung YK; Kim YJ; Kwon KA; Kim JH; Lee JJ; Lee SM; Hahm KB; Lee SM; Jeong JY; Yun SC
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1675-80. PubMed ID: 22849546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
    Greenberg ER; Anderson GL; Morgan DR; Torres J; Chey WD; Bravo LE; Dominguez RL; Ferreccio C; Herrero R; Lazcano-Ponce EC; Meza-Montenegro MM; Peña R; Peña EM; Salazar-Martínez E; Correa P; Martínez ME; Valdivieso M; Goodman GE; Crowley JJ; Baker LH
    Lancet; 2011 Aug; 378(9790):507-14. PubMed ID: 21777974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
    Long X; Chen Q; Yu L; Liang X; Liu W; Lu H
    Helicobacter; 2018 Jun; 23(3):e12485. PubMed ID: 29696736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neither 10- nor 14-Day Sequential Treatment is better than Standard Triple Therapy for Helicobacter Pylori Eradication.
    Warrington E; López-Román O; Tirado Montijo R; Urbina R; Cruz-Correa M; Toro DH
    P R Health Sci J; 2016 Dec; 35(4):203-208. PubMed ID: 27898166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study.
    Lim JH; Lee DH; Choi C; Lee ST; Kim N; Jeong SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Jo HJ; Jang ES; Song Is; Jung HC
    Helicobacter; 2013 Jun; 18(3):180-6. PubMed ID: 23305083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients.
    Abuhammour A; Dajani A; Nounou M; Zakaria M
    Arab J Gastroenterol; 2016 Sep; 17(3):131-136. PubMed ID: 27665525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study.
    Apostolopoulos P; Koumoutsos I; Ekmektzoglou K; Dogantzis P; Vlachou E; Kalantzis C; Tsibouris P; Alexandrakis G
    Scand J Gastroenterol; 2016; 51(2):145-51. PubMed ID: 26435055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth.
    Akpinar Z; Akay S; Unsal B
    Arab J Gastroenterol; 2017 Jun; 18(2):58-61. PubMed ID: 28532623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
    Zullo A; Scaccianoce G; De Francesco V; Ruggiero V; D'Ambrosio P; Castorani L; Bonfrate L; Vannella L; Hassan C; Portincasa P
    Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):647-50. PubMed ID: 23747131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection].
    Campillo A; Amorena E; Ostiz M; Kutz M; LaIglesia M
    Gastroenterol Hepatol; 2016 Nov; 39(9):584-589. PubMed ID: 27084668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate.
    Wu JY; Hsu PI; Wu DC; Graham DY; Wang WM
    Helicobacter; 2014 Jun; 19(3):207-13. PubMed ID: 24612093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.